Perkins Capital Management Inc. acquired a new position in Myomo, Inc. (NYSEAMERICAN:MYO – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 75,000 shares of the company’s stock, valued at approximately $483,000. Perkins Capital Management Inc. owned about 0.25% of Myomo as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Barclays PLC acquired a new position in Myomo during the 3rd quarter valued at about $36,000. Jane Street Group LLC purchased a new stake in shares of Myomo during the third quarter worth about $65,000. Thompson Siegel & Walmsley LLC acquired a new position in shares of Myomo during the fourth quarter valued at about $1,288,000. Stonepine Capital Management LLC purchased a new position in shares of Myomo in the 3rd quarter valued at approximately $401,000. Finally, Calamos Advisors LLC acquired a new stake in Myomo in the 4th quarter worth approximately $189,000. Institutional investors own 44.99% of the company’s stock.
Myomo Price Performance
NYSEAMERICAN MYO opened at $5.38 on Monday. Myomo, Inc. has a 1 year low of $2.51 and a 1 year high of $7.17. The firm has a market cap of $162.75 million, a P/E ratio of -23.39 and a beta of 1.68.
Insider Activity
Analyst Ratings Changes
A number of brokerages have issued reports on MYO. HC Wainwright upped their price target on shares of Myomo from $7.50 to $9.50 and gave the company a “buy” rating in a research note on Wednesday, March 12th. Craig Hallum upped their target price on Myomo from $9.00 to $11.00 and gave the company a “buy” rating in a research report on Tuesday, March 11th. Ascendiant Capital Markets lifted their price target on Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research report on Monday, March 17th. Finally, Alliance Global Partners reissued a “buy” rating on shares of Myomo in a report on Tuesday, March 11th. Five research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $9.75.
Get Our Latest Report on Myomo
About Myomo
Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.
See Also
- Five stocks we like better than Myomo
- What is a Bond Market Holiday? How to Invest and Trade
- AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market
- Why Are These Companies Considered Blue Chips?
- 3 ETFs to Ride the VIX Surge During Market Volatility
- Why Invest in High-Yield Dividend Stocks?
- Why Williams-Sonoma Will Hit Fresh Highs in 2025
Want to see what other hedge funds are holding MYO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Myomo, Inc. (NYSEAMERICAN:MYO – Free Report).
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.